# Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

> **NCT00197236** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 468 (actual)

## Conditions studied

- Hepatitis A

## Interventions

- **BIOLOGICAL:** Havrix™
- **BIOLOGICAL:** Infanrix™
- **BIOLOGICAL:** ActHIB™

## Key facts

- **NCT ID:** NCT00197236
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-11
- **Primary completion:** 2007-12-03
- **Final completion:** 2007-12-03
- **Target enrollment:** 468 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00197236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00197236, "Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00197236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*